Dabigatran reversal: Difference between revisions
ClaireLewis (talk | contribs) No edit summary |
Elcatracho (talk | contribs) |
||
| Line 25: | Line 25: | ||
==See Also== | ==See Also== | ||
*[[Coagulopathy (Main)]] | *[[Coagulopathy (Main)]] | ||
*[[Anticoagulants]] | |||
*[[Idarucizumab]] | *[[Idarucizumab]] | ||
*[[Anticoagulant reversal for life-threatening bleeds]] | *[[Anticoagulant reversal for life-threatening bleeds]] | ||
Revision as of 16:21, 8 March 2021
Background
- If aPTT is <1.5 x control, it is unlikely that significant drug effect is present
- Thrombin Time (TT) is most sensitive; normal TT excludes presence of significant dabigatran
Mild Bleeding
- Local control measures: direct pressure
- Delay next 1-2 doses OR discontinue (as appropriate)
Moderate-Severe Bleeding
- Local control measures: direct pressure/surgical intervention
- Resuscitate with intravenous fluid and / blood products
- Oral charcoal administration if drug taken <2 hours before presentation
- Hemodialysis will remove ~60% of drug taken over prior 2-3 hours
- Consider Idarucizumab (Praxbind): 5 grams IV
Life-Threatening Bleeding
- Idarucizumab (Praxbind): 5 grams IV
In addition, consider above PLUS
- Consider FEIBA[1]
- Consider Recombinant Factor VIIa (no good data)
- Consider Kcentra (PCC): 50 IU/kg IV bolus[2]
- Consider Tranexamic acid
See Also
References
- ↑ Dager WE, Gosselin RC, Roberts AJ. "Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity". Crit Care Med. 2013 May;41(5):e42-6.
- ↑ Eerenberg ES, et al. "Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A randomized, placebo-controlled, crossover study in healthy subjects". Circulation. 2011 Sep 6.